2023
Korber, V., S. A. Stainczyk, R. Kurilov, K. O. Henrich, B. Hero, B. Brors, F. Westermann* and T. Hofer* (2023). "Neuroblastoma arises in early fetal development and its evolutionary duration predicts outcome." Nat Genet 55(4): 619-630.
Bechmann, N., M. L. Moskopp, G. Constantinescu, A. Stell, A. Ernst, F. Berthold, F. Westermann, J. Jiang, L. Lui, E. Nowak, S. Zopp, K. Pacak, M. Peitzsch, A. Schedl, M. Reincke, F. Beuschlein, S. R. Bornstein, M. Fassnacht, G. Eisenhofer and t. International Network of Adrenal (2023). "The asymmetric adrenals: Sexual dimorphism of adrenal tumours." J Clin Endocrinol Metab.
Bechmann, N., F. Westermann and G. Eisenhofer (2023). "HIF and MYC signaling in adrenal neoplasms of the neural crest: implications for pediatrics." Front Endocrinol (Lausanne) 14: 1022192.
Bessonneau-Gaborit, V., J. Cruard, C. Guerin-Charbonnel, J. Derrien, J. B. Alberge, E. Douillard, M. Devic, S. Deshayes, L. Campion, F. Westermann, P. Moreau, C. Herrmann, J. Bourdon, F. Magrangeas and S. Minvielle (2023). "Exploring the impact of dexamethasone on gene regulation in myeloma cells." Life Sci Alliance 6(9).
Bonfiglio, F., V. A. Lasorsa, S. Cantalupo, G. D'Alterio, V. Aievola, A. Boccia, M. Ardito, S. Furini, A. Renieri, M. Morini, S. Stainczyk, F. Westermann, G. Paolella, A. Eva, A. Iolascon and M. Capasso (2023). "Inherited rare variants in homologous recombination and neurodevelopmental genes are associated with increased risk of neuroblastoma." EBioMedicine 87: 104395.
Cobos, F. A., M. J. N. Panah, J. Epps, X. Long, T. K. Man, H. S. Chiu, E. Chomsky, E. Kiner, M. J. Krueger, D. di Bernardo, L. Voloch, J. Molenaar, S. R. van Hooff, F. Westermann, S. Jansky, M. L. Redell, P. Mestdagh and P. Sumazin (2023). "Effective methods for bulk RNA-seq deconvolution using scnRNA-seq transcriptomes." Genome Biol 24(1): 177.
Fiaschetti, G., D. Castelletti, S. Zoller, A. Schramm, C. Schroeder, M. Nagaishi, D. Stearns, M. Mittelbronn, A. Eggert, F. Westermann, H. Ohgaki, T. Shalaby, M. Pruschy, A. Arcaro and M. A. Grotzer (2023). "Correction: Bone morphogenetic protein-7 is a MYC target with prosurvival functions in childhood medulloblastoma." Oncogene 42(2): 168.
Rosswog, C., J. Fassunke, A. Ernst, B. Schomig-Markiefka, S. Merkelbach-Bruse, C. Bartenhagen, M. Cartolano, S. Ackermann, J. Theissen, M. Blattner-Johnson, B. Jones, K. Schramm, J. Altmuller, P. Nurnberg, M. Ortmann, F. Berthold, M. Peifer, R. Buttner, F. Westermann, J. H. Schulte, T. Simon, B. Hero and M. Fischer (2023). "Genomic ALK alterations in primary and relapsed neuroblastoma." Br J Cancer 128(8): 1559-1571.
Weichenhan, D., A. Riedel, C. Meinen, A. Basic, R. Toth, M. Bahr, P. Lutsik, J. Hey, E. Sollier, U. H. Toprak, S. Kelekci, Y. Y. Lin, M. Hakobyan, A. Touzart, A. Goyal, J. A. Wierzbinska, M. Schlesner, F. Westermann, D. B. Lipka and C. Plass (2023). "Translocation t(6;7) in AML-M4 cell line GDM-1 results in MNX1 activation through enhancer-hijacking." Leukemia 37(5): 1147-1150.
*) shared last author
2022
Alborzinia, H., A. F. Florez, S. Kreth, L. M. Bruckner, U. Yildiz, M. Gartlgruber, D. I. Odoni, G. Poschet, K. Garbowicz, C. Shao, C. Klein, J. Meier, P. Zeisberger, M. Nadler-Holly, M. Ziehm, F. Paul, J. Burhenne, E. Bell, M. Shaikhkarami, R. Wurth, S. A. Stainczyk, E. M. Wecht, J. Kreth, M. Buttner, N. Ishaque, M. Schlesner, B. Nicke, C. Stresemann, M. Llamazares-Prada, J. H. Reiling, M. Fischer, I. Amit, M. Selbach, C. Herrmann, S. Wolfl, K. O. Henrich, T. Hofer, A. Trumpp, and F. Westermann. 2022. 'MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis', Nat Cancer, 3: 471-85.
Stainczyk, S. A., and F. Westermann. 2022. 'Neuroblastoma-Telomere maintenance, deregulated signaling transduction and beyond', Int J Cancer, 150: 903-15.
Frank, L., A. Rademacher, N. Mucke, S. M. Tirier, E. Koeleman, C. Knotz, S. Schumacher, S. A. Stainczyk, F. Westermann, S. Frohling, P. Chudasama, and K. Rippe. 2022. 'ALT-FISH quantifies alternative lengthening of telomeres activity by imaging of single-stranded repeats', Nucleic Acids Res, 50: e61.
Gatzweiler, C., J. Ridinger, S. Herter, X. F. Gerloff, D. ElHarouni, Y. Berker, R. Imle, L. Schmitt, S. Kreth, S. Stainczyk, S. Ayhan, S. Najafi, D. Krunic, K. Frese, B. Meder, D. Reuss, P. Fiesel, K. Schramm, M. Blattner-Johnson, D. T. W. Jones, A. Banito, F. Westermann, S. Oppermann, T. Milde, H. Peterziel, O. Witt, and I. Oehme. 2022. 'Functional Therapeutic Target Validation Using Pediatric Zebrafish Xenograft Models', Cancers (Basel), 14.
Khalid, U., M. Simovic, L. A. Hammann, M. Iskar, J. K. L. Wong, R. Kumar, M. Jugold, M. Sill, M. Bolkestein, T. Kolb, M. Hergt, F. Devens, J. Ecker, M. Kool, T. Milde, F. Westermann, A. Benner, J. Lewis, S. Dietrich, S. M. Pfister, P. Lichter, M. Zapatka, and A. Ernst. 2022. 'A synergistic interaction between HDAC- and PARP inhibitors in childhood tumors with chromothripsis', Int J Cancer, 151: 590-606.
Lalchungnunga, H., W. Hao, J. M. Maris, S. Asgharzadeh, K. O. Henrich, F. Westermann, D. A. Tweddle, E. C. Schwalbe, and G. Strathdee. 2022. 'Genome wide DNA methylation analysis identifies novel molecular subgroups and predicts survival in neuroblastoma', Br J Cancer, 127: 2006-15.
Peterziel, H., N. Jamaladdin, D. ElHarouni, X. F. Gerloff, S. Herter, P. Fiesel, Y. Berker, M. Blattner-Johnson, K. Schramm, B. C. Jones, D. Reuss, L. Turunen, A. Friedenauer, T. Holland-Letz, M. Sill, L. Weiser, C. Previti, G. Balasubramanian, N. U. Gerber, J. Gojo, C. Hutter, I. Ora, O. Lohi, A. Kattamis, B. de Wilde, F. Westermann, S. Tippelt, N. Graf, M. Nathrath, M. Sparber-Sauer, A. Sehested, C. M. Kramm, U. Dirksen, O. Kallioniemi, S. M. Pfister, C. M. van Tilburg, D. T. W. Jones, J. Saarela, V. Pietiainen, N. Jager, M. Schlesner, A. Kopp-Schneider, S. Oppermann, T. Milde, O. Witt, and I. Oehme. 2022. 'Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORM', NPJ Precis Oncol, 6: 94.
Wirth, A. K., L. Wange, S. Vosberg, K. O. Henrich, C. Rausch, E. Ozdemir, C. M. Zeller, D. Richter, T. Feuchtinger, M. Kaller, H. Hermeking, P. A. Greif, D. Senft, V. Jurinovic, E. Bahrami, A. K. Jayavelu, F. Westermann, M. Mann, W. Enard, T. Herold, and I. Jeremias. 2022. 'In vivo PDX CRISPR/Cas9 screens reveal mutual therapeutic targets to overcome heterogeneous acquired chemo-resistance', Leukemia, 36: 2863-74.
2021
van Tilburg CM, Pfaff E, Pajtler KW, Langenberg KPS, Fiesel P, Jones BC, Balasubramanian GP, Stark S, Johann PD, Blattner-Johnson M, Schramm K, Dikow N, Hirsch S, Sutter C, Grund K, von Stackelberg A, Kulozik AE, Lissat A, Borkhardt A, Meisel R, Reinhardt D, Klusmann JH, Fleischhack G, Tippelt S, von Schweinitz D, Schmid I, Kramm CM, von Bueren AO, Calaminus G, Vorwerk P, Graf N, Westermann F, Fischer M, Eggert A, Burkhardt B, Wossmann W, Nathrath M, Hecker-Nolting S, Fruhwald MC, Schneider DT, Brecht IB, Ketteler P, Fulda S, Koscielniak E, Meister MT, Scheer M, Hettmer S, Schwab M, Tremmel R, Ora I, Hutter C, Gerber NU, Lohi O, Kazanowska B, Kattamis A, Filippidou M, Goemans B, Zwaan CM, Milde T, Jager N, Wolf S, Reuss D, Sahm F, von Deimling A, Dirksen U, Freitag A, Witt R, Lichter P, Kopp-Schneider A, Jones DTW, Molenaar JJ, Capper D, Pfister SM, Witt O (2021) The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. Cancer discovery 11 (11):2764-2779. doi:10.1158/2159-8290.CD-21-0094
Stainczyk SA, Westermann F (2021) Neuroblastoma-Telomere maintenance, deregulated signaling transduction and beyond. Int J Cancer. doi:10.1002/ijc.33839
Schmitt-Hoffner F, van Rijn S, Toprak UH, Mauermann M, Rosemann F, Heit-Mondrzyk A, Hubner JM, Camgoz A, Hartlieb S, Pfister SM, Henrich KO, Westermann F*, Kool M* (2021) FOXR2 Stabilizes MYCN Protein and Identifies Non-MYCN-Amplified Neuroblastoma Patients With Unfavorable Outcome. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (29):3217-3228. doi:10.1200/JCO.20.02540
Muller M, Rosch L, Najafi S, Gatzweiler C, Ridinger J, Gerloff XF, Jones DTW, Bassler J, Kreth S, Stainczyk S, Frese K, Meder B, Westermann F, Milde T, Peterziel H, Witt O, Oehme I (2021) Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma. Cancers (Basel) 13 (17). doi:10.3390/cancers13174476
Jansky S, Sharma AK, Korber V, Quintero A, Toprak UH, Wecht EM, Gartlgruber M, Greco A, Chomsky E, Grunewald TGP, Henrich KO, Tanay A, Herrmann C, Hofer T, Westermann F (2021) Single-cell transcriptomic analyses provide insights into the developmental origins of neuroblastoma. Nature genetics 53 (5):683-693. doi:10.1038/s41588-021-00806-1
Hartlieb SA, Sieverling L, Nadler-Holly M, Ziehm M, Toprak UH, Herrmann C, Ishaque N, Okonechnikov K, Gartlgruber M, Park YG, Wecht EM, Savelyeva L, Henrich KO, Rosswog C, Fischer M, Hero B, Jones DTW, Pfaff E, Witt O, Pfister SM, Volckmann R, Koster J, Kiesel K, Rippe K, Taschner-Mandl S, Ambros P, Brors B, Selbach M, Feuerbach L, Westermann F (2021) Alternative lengthening of telomeres in childhood neuroblastoma from genome to proteome. Nature communications 12 (1):1269. doi:10.1038/s41467-021-21247-8
Gartlgruber M, Sharma AK, Quintero A, Dreidax D, Jansky S, Park Y-G, Kreth S, Meder J, Doncevic D, Saary P, Toprak UH, Ishaque N, Afanasyeva E, Wecht E, Koster J, Versteeg R, Grünewald TGP, Jones DTW, Pfister SM, Henrich K-O, van Nes J, Herrmann C*, Westermann F* (2021) Super enhancers define regulatory subtypes and cell identity in neuroblastoma. Nature Cancer 2 (1):114-128. doi:10.1038/s43018-020-00145-w
Ecker J, Thatikonda V, Sigismondo G, Selt F, Valinciute G, Oehme I, Muller C, Buhl JL, Ridinger J, Usta D, Qin N, van Tilburg CM, Herold-Mende C, Remke M, Sahm F, Westermann F, Kool M, Wechsler-Reya RJ, Chavez L, Krijgsveld J, Jager N, Pfister SM, Witt O, Milde T (2021) Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastoma. Neuro Oncol 23 (2):226-239. doi:10.1093/neuonc/noaa191
Dieter SM, Siegl C, Codo PL, Huerta M, Ostermann-Parucha AL, Schulz E, Zowada MK, Martin S, Laaber K, Nowrouzi A, Blatter M, Kreth S, Westermann F, Benner A, Uhrig U, Putzker K, Lewis J, Haegebarth A, Mumberg D, Holton SJ, Weiske J, Toepper LM, Scheib U, Siemeister G, Ball CR, Kuster B, Stoehr G, Hahne H, Johannes S, Lange M, Herbst F, Glimm H (2021) Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer. Cell reports 36 (3):109394. doi:10.1016/j.celrep.2021.109394
Afanasyeva EA, Gartlgruber M, Ryl T, Decaesteker B, Denecker G, Monke G, Toprak UH, Florez A, Torkov A, Dreidax D, Herrmann C, Okonechnikov K, Ek S, Sharma AK, Sagulenko V, Speleman F, Henrich KO, Westermann F (2021) Kalirin-RAC controls nucleokinetic migration in ADRN-type neuroblastoma. Life Sci Alliance 4 (5). doi:10.26508/lsa.201900332
2020
Colmenero-Repiso, A., M. A. Gomez-Munoz, I. Rodriguez-Prieto, A. Amador-Alvarez, K. O. Henrich, D. Pascual-Vaca, K. Okonechnikov, E. Rivas, F. Westermann, R. Pardal, and F. M. Vega. 2020. 'Identification of VRK1 as a New Neuroblastoma Tumor Progression Marker Regulating Cell Proliferation', Cancers (Basel), 12.
Ecker, J., V. Thatikonda, G. Sigismondo, F. Selt, G. Valinciute, I. Oehme, C. Muller, J. L. Buhl, J. Ridinger, D. Usta, N. Qin, C. M. van Tilburg, C. Herold-Mende, M. Remke, F. Sahm, F. Westermann, M. Kool, R. J. Wechsler-Reya, L. Chavez, J. Krijgsveld, N. Jager, S. M. Pfister, O. Witt, and T. Milde. 2020. 'Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastoma', Neuro Oncol.
George, S. L., F. Lorenzi, D. King, S. Hartlieb, J. Campbell, H. Pemberton, U. H. Toprak, K. Barker, J. Tall, B. M. da Costa, M. L. van den Boogaard, M. E. M. Dolman, J. J. Molenaar, H. E. Bryant, F. Westermann, C. J. Lord, and L. Chesler. 2020. 'Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma', EBioMedicine, 59: 102971.
2019
Claeys, S., G. Denecker, K. Durinck, B. Decaesteker, L. M. Mus, S. Loontiens, S. Vanhauwaert, K. Althoff, C. Wigerup, D. Bexell, E. Dolman, K. O. Henrich, L. Wehrmann, E. M. Westerhout, J. B. Demoulin, C. Kumps, T. Van Maerken, G. Laureys, C. Van Neste, B. De Wilde, O. De Wever, F. Westermann, R. Versteeg, J. J. Molenaar, S. Pahlman, J. H. Schulte, K. De Preter, and F. Speleman. 2019. 'ALK positively regulates MYCN activity through repression of HBP1 expression', Oncogene, 38: 2690-705.
Jones, D. T. W., A. Banito, T. G. P. Grunewald, M. Haber, N. Jager, M. Kool, T. Milde, J. J. Molenaar, A. Nabbi, T. J. Pugh, G. Schleiermacher, M. A. Smith, F. Westermann, and S. M. Pfister. 2019. 'Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours', Nat Rev Cancer, 19: 420-38.
Musa, J., F. Cidre-Aranaz, M. M. Aynaud, M. F. Orth, M. M. L. Knott, O. Mirabeau, G. Mazor, M. Varon, T. L. B. Holting, S. Grossetete, M. Gartlgruber, D. Surdez, J. S. Gerke, S. Ohmura, A. Marchetto, M. Dallmayer, M. C. Baldauf, S. Stein, G. Sannino, J. Li, L. Romero-Perez, F. Westermann, W. Hartmann, U. Dirksen, M. Gymrek, N. D. Anderson, A. Shlien, B. Rotblat, T. Kirchner, O. Delattre, and T. G. P. Grunewald. 2019. 'Cooperation of cancer drivers with regulatory germline variants shapes clinical outcomes', Nat Commun, 10: 4128.
Soriano, A., M. Masanas, A. Boloix, N. Masia, L. Paris-Coderch, O. Piskareva, C. Jimenez, K. O. Henrich, J. Roma, F. Westermann, R. L. Stallings, C. Sabado, J. S. de Toledo, A. Santamaria, S. Gallego, and M. F. Segura. 2019. 'Functional high-throughput screening reveals miR-323a-5p and miR-342-5p as new tumor-suppressive microRNA for neuroblastoma', Cell Mol Life Sci, 76: 2231-43.
2018
Ogorodnikov A, Levin M, Tattikota S, Tokalov S, Hoque M, Scherzinger D, Marini F, Poetsch A, Binder H, Macher-Göppinger S, Probst HC, Tian B, Schaefer M, Lackner KJ, Westermann F, Danckwardt S. Transcriptome 3'end organization by PCF11 links alternative polyadenylation to formation and neuronal differentiation of neuroblastoma. Nat Commun. 2018 Dec 14;9(1):5331. doi: 10.1038/s41467-018-07580-5. PubMed PMID: 30552333.
Ackermann S, Cartolano M, Hero B, Welte A, Kahlert Y, Roderwieser A, Bartenhagen C, Walter E, Gecht J, Kerschke L, Volland R, Menon R, Heuckmann JM, Gartlgruber M, Hartlieb S, Henrich KO, Okonechnikov K, Altmüller J, Nürnberg P, Lefever S, de Wilde B, Sand F, Ikram F, Rosswog C, Fischer J, Theissen J, Hertwig F, Singhi AD, Simon T, Vogel W, Perner S, Krug B, Schmidt M, Rahmann S, Achter V, Lang U, Vokuhl C, Ortmann M, Büttner R, Eggert A, Speleman F, O'Sullivan RJ, Thomas RK, Berthold F, Vandesompele J, Schramm A*, Westermann F*, Schulte JH*, Peifer M*, Fischer M*. A mechanistic classification of clinical phenotypes in neuroblastoma. Science. 2018 Dec 7;362(6419):1165-1170. doi: 10.1126/science.aat6768. PubMed PMID: 30523111.* equal contribution
Shen J, Najafi S, Stäble S, Fabian J, Koeneke E, Kolbinger FR, Wrobel JK, Meder B, Distel M, Heimburg T, Sippl W, Jung M, Peterziel H, Kranz D, Boutros M, Westermann F, Witt O, Oehme I. A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment. Cell Death Differ. 2018 Dec;25(12):2053-2070. doi: 10.1038/s41418-018-0080-0. Epub 2018 Mar 7. PubMed PMID: 29515255; PubMed Central PMCID: PMC6261943.
Decaesteker B, Denecker G, Van Neste C, Dolman EM, Van Loocke W, Gartlgruber M, Nunes C, De Vloed F, Depuydt P, Verboom K, Rombaut D, Loontiens S, De Wyn J, Kholosy WM, Koopmans B, Essing AHW, Herrmann C, Dreidax D, Durinck K, Deforce D, van Nieuwerburgh F, Henssen A, Versteeg R, Boeva V, Schleiermacher G, van Nes J, Mestdagh P, Vanhauwaert S, Schulte JH, Westermann F, Molenaar JJ, De Preter K, Speleman F. TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targets. Nat Commun. 2018 Nov 19;9(1):4866. doi: 10.1038/s41467-018-06699-9. PubMed PMID: 30451831; PubMed Central PMCID: PMC6242972.
Kolbinger FR, Koeneke E, Ridinger J, Heimburg T, Müller M, Bayer T, Sippl W, Jung M, Gunkel N, Miller AK, Westermann F, Witt O, Oehme I. The HDAC6/8/10 inhibitor TH34 induces DNA damage-mediated cell death in human high-grade neuroblastoma cell lines. Arch Toxicol. 2018 Aug;92(8):2649-2664. doi: 10.1007/s00204-018-2234-8. Epub 2018 Jun 9. PubMed PMID: 29947893; PubMed Central PMCID: PMC6063332.
Gröbner SN, Worst BC, Weischenfeldt J, Buchhalter I, Kleinheinz K, Rudneva VA, Johann PD, Balasubramanian GP, Segura-Wang M, Brabetz S, Bender S, Hutter B, Sturm D, Pfaff E, Hübschmann D, Zipprich G, Heinold M, Eils J, Lawerenz C, Erkek S, Lambo S, Waszak S, Blattmann C, Borkhardt A, Kuhlen M, Eggert A, Fulda S, Gessler M, Wegert J, Kappler R, Baumhoer D, Burdach S, Kirschner-Schwabe R, Kontny U, Kulozik AE, Lohmann D, Hettmer S, Eckert C, Bielack S, Nathrath M, Niemeyer C, Richter GH, Schulte J, Siebert R, Westermann F, Molenaar JJ, Vassal G, Witt H, Burkhardt B, Kratz CP, Witt O, van Tilburg CM, Kramm CM, Fleischhack G, Dirksen U, Rutkowski S, Frühwald M, von Hoff K, Wolf S, Klingebiel T, Koscielniak E, Landgraf P, Koster J, Resnick AC, Zhang J, Liu Y, Zhou X, Waanders AJ, Zwijnenburg DA, Raman P, Brors B, Weber UD, Northcott PA, Pajtler KW, Kool M, Piro RM, Korbel JO, Schlesner M, Eils R, Jones DTW, Lichter P, Chavez L, Zapatka M, Pfister SM; ICGC PedBrain-Seq Project; ICGC MMML-Seq Project. Author Correction: The landscape of genomic alterations across childhood cancers. Nature. 2018 Jul;559(7714):E10. doi: 10.1038/s41586-018-0167-2. PubMed PMID: 29875405.
2017
Ryl T, Kuchen EE, Bell E, Shao C, Flórez AF, Mönke G, Gogolin S, Friedrich M, Lamprecht F, Westermann F*, Höfer T.* Cell-Cycle Position of Single MYC-Driven Cancer Cells Dictates Their Susceptibility to a Chemotherapeutic Drug. Cell Syst. 2017 Sep 27;5(3):237-250.e8. doi: 10.1016/j.cels.2017.07.005. Epub 2017 Aug 23. PubMed PMID: 28843484. *equal contribution
Layer JP, Kronmüller MT, Quast T, van den Boorn-Konijnenberg D, Effern M, Hinze D, Althoff K, Schramm A, Westermann F, Peifer M, Hartmann G, Tüting T, Kolanus W, Fischer M, Schulte J, Hölzel M. Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression. Oncoimmunology. 2017 Apr 28;6(6):e1320626. doi: 10.1080/2162402X.2017.1320626. eCollection 2017. PubMed PMID: 28680756; PubMed Central PMCID: PMC5486176.
2016
Henrich KO, Bender S, Saadati M, Dreidax D, Gartlgruber M, Shao C, Herrmann C, Wiesenfarth M, Parzonka M, Wehrmann L, Fischer M, Duffy DJ, Bell E, Torkov A, Schmezer P, Plass C, Höfer T, Benner A, Pfister SM, Westermann F. Integrative Genome-Scale Analysis Identifies Epigenetic Mechanisms of Transcriptional Deregulation in Unfavorable Neuroblastomas. Cancer Res. 2016 Sep 15;76(18):5523-37. doi: 10.1158/0008-5472.CAN-15-2507. Epub 2016 Sep 7. PubMed PMID: 27635046.
Bulashevska S, Priest C, Speicher D, Zimmermann J, Westermann F, Cremers AB. SwitchFinder - a novel method and query facility for discovering dynamic gene expression patterns. BMC Bioinformatics. 2016 Dec 15;17(1):532. PubMed PMID: 27978814; PubMed Central PMCID: PMC5160026.
Duffy DJ, Krstic A, Schwarzl T, Halasz M, Iljin K, Fey D, Haley B, Whilde J, Haapa-Paananen S, Fey V, Fischer M, Westermann F, Henrich KO, Bannert S, Higgins DG, Kolch W. Wnt signalling is a bi-directional vulnerability of cancer cells. Oncotarget. 2016 Sep 13;7(37):60310-60331. doi: 10.18632/oncotarget.11203. PubMed PMID: 27531891; PubMed Central PMCID: PMC5312386.
Worst BC, van Tilburg CM, Balasubramanian GP, Fiesel P, Witt R, Freitag A, Boudalil M, Previti C, Wolf S, Schmidt S, Chotewutmontri S, Bewerunge-Hudler M, Schick M, Schlesner M, Hutter B, Taylor L, Borst T, Sutter C, Bartram CR, Milde T, Pfaff E, Kulozik AE, von Stackelberg A, Meisel R, Borkhardt A, Reinhardt D, Klusmann JH, Fleischhack G, Tippelt S, Dirksen U, Jürgens H, Kramm CM, von Bueren AO, Westermann F, Fischer M, Burkhardt B, Wößmann W, Nathrath M, Bielack SS, Frühwald MC, Fulda S, Klingebiel T, Koscielniak E, Schwab M, Tremmel R, Driever PH, Schulte JH, Brors B, von Deimling A, Lichter P, Eggert A, Capper D, Pfister SM, Jones DT, Witt O. Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study. Eur J Cancer. 2016 Sep;65:91-101. doi: 10.1016/j.ejca.2016.06.009. Epub 2016 Jul 29. PubMed PMID: 27479119.
Hasche D, Stephan S, Savelyeva L, Westermann F, Rösl F, Vinzón SE. Establishment of an Immortalized Skin Keratinocyte Cell Line Derived from the Animal Model Mastomys coucha. PLoS One. 2016 Aug 17;11(8):e0161283. doi: 10.1371/journal.pone.0161283. eCollection 2016. PubMed PMID: 27533138; PubMed Central PMCID: PMC4988767.
Textor S, Bossler F, Henrich KO, Gartlgruber M, Pollmann J, Fiegler N, Arnold A, Westermann F, Waldburger N, Breuhahn K, Golfier S, Witzens-Harig M, Cerwenka A. The proto-oncogene Myc drives expression of the NK cell-activating NKp30 ligand B7-H6 in tumor cells. Oncoimmunology. 2016 Jul 28;5(7):e1116674. doi: 10.1080/2162402X.2015.1116674. eCollection 2016 Jul. PubMed PMID: 27622013; PubMed Central PMCID: PMC5007025.
Henssen A, Althoff K, Odersky A, Beckers A, Koche R, Speleman F, Schäfers S, Bell E, Nortmeyer M, Westermann F, De Preter K, Florin A, Heukamp L, Spruessel A, Astrahanseff K, Lindner S, Sadowski N, Schramm A, Astorgues-Xerri L, Riveiro ME, Eggert A, Cvitkovic E, Schulte JH. Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition. Clin Cancer Res. 2016 May 15;22(10):2470-81. doi: 10.1158/1078-0432.CCR-15-1449. Epub 2015 Dec 2. PubMed PMID: 26631615.
Zhang S, Wei JS, Li SQ, Badgett TC, Song YK, Agarwal S, Coarfa C, Tolman C, Hurd L, Liao H, He J, Wen X, Liu Z, Thiele CJ, Westermann F, Asgharzadeh S, Seeger RC, Maris JM, Guidry Auvil JM, Smith MA, Kolaczyk ED, Shohet J, Khan J. MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma. Cancer Lett. 2016 Feb 28;371(2):214-24. doi: 10.1016/j.canlet.2015.11.045. Epub 2015 Dec 10. PubMed PMID: 26683771; PubMed Central PMCID: PMC4738031.
2015
Peifer M, Hertwig F, Roels F, Dreidax D, Gartlgruber M, Menon R, Krämer A, Roncaioli JL, Sand F, Heuckmann JM, Ikram F, Schmidt R, Ackermann S, Engesser A, Kahlert Y, Vogel W, Altmüller J, Nürnberg P, Thierry-Mieg J, Thierry-Mieg D, Mariappan A, Heynck S, Mariotti E, Henrich KO, Gloeckner C, Bosco G, Leuschner I, Schweiger MR, Savelyeva L, Watkins SC, Shao C, Bell E, Höfer T, Achter V, Lang U, Theissen J, Volland R, Saadati M, Eggert A, de Wilde B, Berthold F, Peng Z, Zhao C, Shi L, Ortmann M, Büttner R, Perner S, Hero B, Schramm A, Schulte JH, Herrmann C, O'Sullivan RJ, Westermann F*, Thomas RK*, Fischer M*. Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature. 2015 Oct 29;526(7575):700-4. doi: 10.1038/nature14980. Epub 2015 Oct 14. PubMed PMID: 26466568; PubMed Central PMCID: PMC4881306.
Ikram F, Ackermann S, Kahlert Y, Volland R, Roels F, Engesser A, Hertwig F, Kocak H, Hero B, Dreidax D, Henrich KO, Berthold F, Nürnberg P, Westermann F, Fischer M. Transcription factor activating protein 2 beta (TFAP2B) mediates noradrenergic neuronal differentiation in neuroblastoma. Mol Oncol. 2016 Feb;10(2):344-59. doi: 10.1016/j.molonc.2015.10.020. Epub 2015 Nov 7. PubMed PMID: 26598443; PubMed Central PMCID: PMC5528952.
Duffy DJ, Krstic A, Halasz M, Schwarzl T, Fey D, Iljin K, Mehta JP, Killick K, Whilde J, Turriziani B, Haapa-Paananen S, Fey V, Fischer M, Westermann F, Henrich KO, Bannert S, Higgins DG, Kolch W. Integrative omics reveals MYCN as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma. Oncotarget. 2015 Dec 22;6(41):43182-201. doi: 10.18632/oncotarget.6568. PubMed PMID: 26673823; PubMed Central PMCID: PMC4791225.
Fey D, Halasz M, Dreidax D, Kennedy SP, Hastings JF, Rauch N, Munoz AG, Pilkington R, Fischer M, Westermann F, Kolch W, Kholodenko BN, Croucher DR. Signaling pathway models as biomarkers: Patient-specific simulations of JNK activity predict the survival of neuroblastoma patients. Sci Signal. 2015 Dec 22;8(408):ra130. doi: 10.1126/scisignal.aab0990. PubMed PMID: 26696630.
Beckers A, Van Peer G, Carter DR, Gartlgruber M, Herrmann C, Agarwal S, Helsmoortel HH, Althoff K, Molenaar JJ, Cheung BB, Schulte JH, Benoit Y, Shohet JM, Westermann F, Marshall GM, Vandesompele J, De Preter K, Speleman F. MYCN-driven regulatory mechanisms controlling LIN28B in neuroblastoma. Cancer Lett. 2015 Sep 28;366(1):123-32. doi: 10.1016/j.canlet.2015.06.015. Epub 2015 Jun 26. PubMed PMID: 26123663; PubMed Central PMCID: PMC4837470.
Schramm A, Köster J, Assenov Y, Althoff K, Peifer M, Mahlow E, Odersky A, Beisser D, Ernst C, Henssen AG, Stephan H, Schröder C, Heukamp L, Engesser A, Kahlert Y, Theissen J, Hero B, Roels F, Altmüller J, Nürnberg P, Astrahantseff K, Gloeckner C, De Preter K, Plass C, Lee S, Lode HN, Henrich KO, Gartlgruber M, Speleman F, Schmezer P, Westermann F, Rahmann S, Fischer M, Eggert A, Schulte JH. Mutational dynamics between primary and relapse neuroblastomas. Nat Genet. 2015 Aug;47(8):872-7. doi: 10.1038/ng.3349. Epub 2015 Jun 29. PubMed PMID: 26121086.
Harder N, Batra R, Diessl N, Gogolin S, Eils R, Westermann F, König R, Rohr K. Large-scale tracking and classification for automatic analysis of cell migration and proliferation, and experimental optimization of high-throughput screens of neuroblastoma cells. Cytometry A. 2015 Jun;87(6):524-40. doi: 10.1002/cyto.a.22632. Epub 2015 Jan 28. PubMed PMID: 25630981.
Althoff K, Beckers A, Bell E, Nortmeyer M, Thor T, Sprüssel A, Lindner S, De Preter K, Florin A, Heukamp LC, Klein-Hitpass L, Astrahantseff K, Kumps C, Speleman F, Eggert A, Westermann F, Schramm A, Schulte JH. A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies. Oncogene. 2015 Jun;34(26):3357-68. doi: 10.1038/onc.2014.269. Epub 2014 Sep 1. PubMed PMID: 25174395; PubMed Central PMCID: PMC4487199.
2014
Oberthuer A, Juraeva D, Hero B, Volland R, Sterz C, Schmidt R, Faldum A, Kahlert Y, Engesser A, Asgharzadeh S, Seeger R, Ohira M, Nakagawara A, Scaruffi P, Tonini GP, Janoueix-Lerosey I, Delattre O, Schleiermacher G, Vandesompele J, Speleman F, Noguera R, Piqueras M, Bénard J, Valent A, Avigad S, Yaniv I, Grundy RG, Ortmann M, Shao C, Schwab M, Eils R, Simon T, Theissen J, Berthold F, Westermann F, Brors B, Fischer M. Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers. Clin Cancer Res. 2015 Apr 15;21(8):1904-15. doi: 10.1158/1078-0432.CCR-14-0817. Epub 2014 Sep 17. PubMed PMID: 25231397.
Dreidax D, Bannert S, Henrich KO, Schröder C, Bender S, Oakes CC, Lindner S, Schulte JH, Duffy D, Schwarzl T, Saadati M, Ehemann V, Benner A, Pfister S, Fischer M, Westermann F. p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCN-amplified neuroblastomas. Hum Mol Genet. 2014 Dec 20;23(25):6826-37. doi: 10.1093/hmg/ddu406. Epub 2014 Aug 7. PubMed PMID: 25104850.
Michaelis M, Agha B, Rothweiler F, Löschmann N, Voges Y, Mittelbronn M, Starzetz T, Harter PN, Abhari BA, Fulda S, Westermann F, Riecken K, Spek S, Langer K, Wiese M, Dirks WG, Zehner R, Cinatl J, Wass MN, Cinatl J Jr. Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen. Sci Rep. 2015 Feb 3;5:8202. doi: 10.1038/srep08202. PubMed PMID: 25644037; PubMed Central PMCID: PMC4314641.
Fabian J, Lodrini M, Oehme I, Schier MC, Thole TM, Hielscher T, Kopp-Schneider A, Opitz L, Capper D, von Deimling A, Wiegand I, Milde T, Mahlknecht U, Westermann F, Popanda O, Roels F, Hero B, Berthold F, Fischer M, Kulozik AE, Witt O, Deubzer HE. GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3. Cancer Res. 2014 May 1;74(9):2604-16. doi: 10.1158/0008-5472.CAN-13-1904. Epub 2014 Jan 13. PubMed PMID: 24419085.
Fiaschetti G, Schroeder C, Castelletti D, Arcaro A, Westermann F, Baumgartner M, Shalaby T, Grotzer MA. NOTCH ligands JAG1 and JAG2 as critical pro-survival factors in childhood medulloblastoma. Acta Neuropathol Commun. 2014 Apr 7;2:39. doi: 10.1186/2051-5960-2-39. PubMed PMID: 24708907; PubMed Central PMCID: PMC4023630.
Savelyeva L, Brueckner LM. Molecular characterization of common fragile sites as a strategy to discover cancer susceptibility genes. Cell Mol Life Sci. 2014 Dec;71(23):4561-75. doi: 10.1007/s00018-014-1723-z. Epub 2014 Sep 18. Review. PubMed PMID: 25231336.
2013
Dreidax D, Gogolin S, Schroeder C, Muth D, Brueckner LM, Hess EM, Zapatka M, Theißen J, Fischer M, Ehemann V, Schwab M, Savelyeva L, Westermann F. Low p14ARF expression in neuroblastoma cells is associated with repressed histone mark status, and enforced expression induces growth arrest and apoptosis. Hum Mol
Genet. 2013 May 1;22(9):1735-45. doi: 10.1093/hmg/ddt020. Epub 2013 Jan 23. PubMed PMID: 23343716.
Gogolin S, Batra R, Harder N, Ehemann V, Paffhausen T, Diessl N, Sagulenko V, Benner A, Gade S, Nolte I, Rohr K, König R, Westermann F. MYCN-mediated overexpression of mitotic spindle regulatory genes and loss of p53-p21 function
jointly support the survival of tetraploid neuroblastoma cells. Cancer Lett. 2013 Apr 30;331(1):35-45. doi: 10.1016/j.canlet.2012.11.028. Epub 2012 Nov 24. PubMed PMID: 23186832.
Gogolin S, Ehemann V, Becker G, Brueckner LM, Dreidax D, Bannert S, Nolte I, Savelyeva L, Bell E, Westermann F. CDK4 inhibition restores G(1)-S arrest in MYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA
damage. Cell Cycle. 2013 Apr 1;12(7):1091-104. doi: 10.4161/cc.24091. Epub 2013 Mar 5. PubMed PMID: 23462184; PubMed Central PMCID: PMC3646865.
Löschmann N, Michaelis M, Rothweiler F, Zehner R, Cinatl J, Voges Y, Sharifi M, Riecken K, Meyer J, von Deimling A, Fichtner I, Ghafourian T, Westermann F, Cinatl J Jr. Testing of SNS-032 in a Panel of Human Neuroblastoma Cell Lines with Acquired Resistance to a Broad Range of Drugs. Transl Oncol. 2013 Dec 1;6(6):685-96. eCollection 2013 Dec 1. PubMed PMID: 24466371; PubMed Central PMCID: PMC3890703.
Salm F, Cwiek P, Ghosal A, Lucia Buccarello A, Largey F, Wotzkow C, Höland K, Styp-Rekowska B, Djonov V, Zlobec I, Bodmer N, Gross N, Westermann F, Schäfer SC, Arcaro A. RNA interference screening identifies a novel role for autocrine
fibroblast growth factor signaling in neuroblastoma chemoresistance. Oncogene. 2013 Aug 22;32(34):3944-53. doi: 10.1038/onc.2012.416. Epub 2012 Oct 1. PubMed PMID: 23027129.
Bell E, Ponthan F, Whitworth C, Westermann F, Thomas H, Redfern CP. Cell survival signalling through PPARδ and arachidonic acid metabolites in neuroblastoma. PLoS One. 2013 Jul 9;8(7):e68859. doi: 10.1371/journal.pone.0068859. Print 2013. PubMed PMID: 23874790; PubMed Central PMCID: PMC3706415.
Lodrini M, Oehme I, Schroeder C, Milde T, Schier MC, Kopp-Schneider A, Schulte JH, Fischer M, De Preter K, Pattyn F, Castoldi M, Muckenthaler MU, Kulozik AE, Westermann F, Witt O, Deubzer HE. MYCN and HDAC2 cooperate to repress
miR-183 signaling in neuroblastoma. Nucleic Acids Res. 2013 Jul;41(12):6018-33. doi: 10.1093/nar/gkt346. Epub 2013 Apr 26. PubMed PMID: 23625969; PubMed Central PMCID: PMC3695529.
Asada K, Watanabe N, Nakamura Y, Ohira M, Westermann F, Schwab M, Nakagawara A, Ushijima T. Stronger prognostic power of the CpG island methylator phenotype than methylation of individual genes in neuroblastomas. Jpn J Clin Oncol. 2013 Jun;43(6):641-5. doi: 10.1093/jjco/hyt058. Epub 2013 Apr 25. PubMed PMID: 23619990.
Kocak H, Ackermann S, Hero B, Kahlert Y, Oberthuer A, Juraeva D, Roels F, Theissen J, Westermann F, Deubzer H, Ehemann V, Brors B, Odenthal M, Berthold F, Fischer M. Hox-C9 activates the intrinsic pathway of apoptosis and is associated with spontaneous regression in neuroblastoma. Cell Death Dis. 2013 Apr 11;4:e586. doi: 10.1038/cddis.2013.84. PubMed PMID: 23579273; PubMed Central PMCID: PMC3668636.
Kumps C, Fieuw A, Mestdagh P, Menten B, Lefever S, Pattyn F, De Brouwer S, Sante T, Schulte JH, Schramm A, Van Roy N, Van Maerken T, Noguera R, Combaret V, Devalck C, Westermann F, Laureys G, Eggert A, Vandesompele J, De Preter K, Speleman F. Focal DNA copy number changes in neuroblastoma target MYCN regulated genes. PLoS One. 2013;8(1):e52321. doi: 10.1371/journal.pone.0052321. Epub 2013 Jan 4. PubMed PMID: 23308108; PubMed Central PMCID: PMC3537730.
Carotenuto M, Pedone E, Diana D, de Antonellis P, Džeroski S, Marino N, Navas L, Di Dato V, Scoppettuolo MN, Cimmino F, Correale S, Pirone L, Monti SM, Bruder E, Zenko B, Slavkov I, Pastorino F, Ponzoni M, Schulte JH, Schramm A, Eggert A,
Westermann F, Arrigoni G, Accordi B, Basso G, Saviano M, Fattorusso R, Zollo M. Neuroblastoma tumorigenesis is regulated through the Nm23-H1/h-Prune C-terminal interaction. Sci Rep. 2013;3:1351. doi: 10.1038/srep01351. PubMed PMID: 23448979; PubMed Central PMCID: PMC3584926.
Brueckner LM, Hess EM, Schwab M, Savelyeva L. Instability at the FRA8I common fragile site disrupts the genomic integrity of the KIAA0146, CEBPD and PRKDC genes in colorectal cancer. Cancer Lett. 2013 Aug 9;336(1):85-95. doi:
10.1016/j.canlet.2013.04.007. Epub 2013 Apr 16. PubMed PMID: 23603433.
2012
Henrich KO, Schwab M, Westermann F. 1p36 tumor suppression--a matter of dosage? Cancer Res. 2012 Dec 1;72(23):6079-88. doi: 10.1158/0008-5472.CAN-12-2230. Epub 2012 Nov 20. Review. PubMed PMID: 23172308.
Batra R, Harder N, Gogolin S, Diessl N, Soons Z, Jäger-Schmidt C, Lawerenz C, Eils R, Rohr K, Westermann F, König R. Time-lapse imaging of neuroblastoma cells to determine cell fate upon gene knockdown. PLoS One. 2012;7(12):e50988. doi: 10.1371/journal.pone.0050988. Epub 2012 Dec 12. PubMed PMID: 23251412; PubMed Central PMCID: PMC3521006.
De Brouwer S, Mestdagh P, Lambertz I, Pattyn F, De Paepe A, Westermann F, Schroeder C, Schulte JH, Schramm A, De Preter K, Vandesompele J, Speleman F. Dickkopf-3 is regulated by the MYCN-induced miR-17-92 cluster in neuroblastoma. Int J Cancer. 2012 Jun 1;130(11):2591-8. doi: 10.1002/ijc.26295. Epub 2011 Aug 30. PubMed PMID: 21796614.
Korshunov A, Remke M, Kool M, Hielscher T, Northcott PA, Williamson D, Pfaff E, Witt H, Jones DT, Ryzhova M, Cho YJ, Wittmann A, Benner A, Weiss WA, von Deimling A, Scheurlen W, Kulozik AE, Clifford SC, Peter Collins V, Westermann F, Taylor MD, Lichter P, Pfister SM. Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. Acta Neuropathol. 2012 Apr;123(4):515-27. doi: 10.1007/s00401-011-0918-8. Epub 2011 Dec 9. PubMed PMID: 22160402.
Brueckner LM, Sagulenko E, Hess EM, Zheglo D, Blumrich A, Schwab M, Savelyeva L. Genomic rearrangements at the FRA2H common fragile site frequently involve non-homologous recombination events across LTR and L1(LINE) repeats. Hum Genet. 2012 Aug;131(8):1345-59. doi: 10.1007/s00439-012-1165-3. Epub 2012 Apr 5. PubMed PMID: 22476624.